<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351766</url>
  </required_header>
  <id_info>
    <org_study_id>DA029445</org_study_id>
    <secondary_id>R21DA029445</secondary_id>
    <nct_id>NCT01351766</nct_id>
  </id_info>
  <brief_title>Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation</brief_title>
  <official_title>Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, College Park</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to develop a specialized behavioral activation treatment&#xD;
      for smoking in youths ages 18-21 with elevated depressive symptoms. In the first phase we&#xD;
      utilize focus groups and pilot testing with 15 youths to develop the behavioral activation&#xD;
      smoking treatment for youth. In Phase II, we will conduct an open-label trial of the new&#xD;
      treatment that will include 8 weeks of transdermal nicotine patch, which will begin at the&#xD;
      time of quitting smoking. Participants will be followed over 26 weeks post-quit date. A&#xD;
      subset of participants will also undergo an fMRI session to examine reward sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. 18-21 years of age,&#xD;
&#xD;
        2. a regular smoker for at least 6 months&#xD;
&#xD;
        3. currently smoking an average of at least 5 cigarettes per day&#xD;
&#xD;
        4. want to quit smoking&#xD;
&#xD;
        5. report current elevated depressive symptoms&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date</measure>
    <time_frame>12 weeks post quit date</time_frame>
    <description>7 days of smoking abstinence confirmed via expired carbon monoxide at 12 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Behavioral Activation for Smoking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended.&#xD;
Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Nicotine Patch</intervention_name>
    <description>Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.</description>
    <arm_group_label>Behavioral Activation for Smoking</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between 18 and 21 years of age&#xD;
&#xD;
          -  a regular smoker for at least 6 months&#xD;
&#xD;
          -  currently smoking an average of at least 5 cigarettes per day&#xD;
&#xD;
          -  want to quit smoking&#xD;
&#xD;
          -  report current elevated depressive symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current Axis I disorder&#xD;
&#xD;
          -  psychoactive substance dependence (excluding nicotine dependence) within the past 6&#xD;
             months&#xD;
&#xD;
          -  current use of psychotropic medication or participation in any form of psychotherapy&#xD;
&#xD;
          -  a history of significant medical condition (e.g., cardiovascular , neurological,&#xD;
             gastrointestinal), pregnancy and/or breast feeding, or other systemic illness&#xD;
&#xD;
          -  limited mental competency [Mini Mental State Examination score &lt; 23] and/or the&#xD;
             inability to give informed, voluntary, written consent to participate&#xD;
&#xD;
          -  current use of any pharmacotherapy for smoking cessation not provided by the&#xD;
             researchers during the quit attempt&#xD;
&#xD;
        Additional Exclusion criteria only for the fMRI portion:&#xD;
&#xD;
          -  cerebrovascular disease&#xD;
&#xD;
          -  high blood pressure&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  use of psychotropic medications in 3 weeks prior to participation in fMRI protocol&#xD;
&#xD;
          -  exposure to extreme trauma&#xD;
&#xD;
          -  lifetime history of mania, psychosis, or pervasive developmental disorder,&#xD;
&#xD;
          -  being ambidextrous or left handed&#xD;
&#xD;
          -  any metal implants, heart pacemaker, permanent retainer&#xD;
&#xD;
          -  tattoos containing metal dyes&#xD;
&#xD;
          -  claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura MacPherson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, College Park</name>
      <address>
        <city>College Park</city>
        <state>Maryland</state>
        <zip>20742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <results_first_submitted>September 10, 2020</results_first_submitted>
  <results_first_submitted_qc>November 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2020</results_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Laura MacPherson</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Behavioral Activation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Behavioral Activation for Smoking</title>
          <description>Eight, 60-minute group sessions over an 8 week period&#xD;
Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking, and will continue after treatment sessions have ended</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population is not different from the assignment in Participant Flow.</population>
      <group_list>
        <group group_id="B1">
          <title>Behavioral Activation for Smoking</title>
          <description>Behavioral Activation for Smoking (BATSY) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also be provided 8 weeks of the transdermal nicotine patch.&#xD;
Transdermal Nicotine Patch: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.00" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date</title>
        <description>7 days of smoking abstinence confirmed via expired carbon monoxide at 12 weeks</description>
        <time_frame>12 weeks post quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Behavioral Activation for Smoking</title>
            <description>Eight, 60-minute group sessions over an 8 week period&#xD;
Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking, and will continue after treatment sessions have ended</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date</title>
          <description>7 days of smoking abstinence confirmed via expired carbon monoxide at 12 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 20 weeks.</time_frame>
      <desc>Definition of adverse event and/or serious adverse event does not differ from clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Behavioral Activation for Smoking</title>
          <description>Eight, 60-minute group sessions over an 8 week period&#xD;
Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking, and will continue after treatment sessions have ended</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura MacPherson</name_or_title>
      <organization>University of Maryland</organization>
      <phone>6198578425</phone>
      <email>lauramac.phd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

